Iloperidone

Generic Name
Iloperidone
Brand Names
Fanapt
Drug Type
Small Molecule
Chemical Formula
C24H27FN2O4
CAS Number
133454-47-4
Unique Ingredient Identifier
VPO7KJ050N
Background

Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals ga...

Indication

Treatment of acute schizophrenia.

Associated Conditions
Schizophrenia
Associated Therapies
-
Clinical Trials
Related News

Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

Phase 2
Terminated
Conditions
Post Traumatic Stress Disorder
Interventions
Drug: Iloperidone
Drug: Placebo
First Posted Date
2013-08-06
Last Posted Date
2020-02-11
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
1
Registration Number
NCT01917318
Locations
🇺🇸

University of Colorado Depression Center; Clinical and Translational Research Center (CTRC), Aurora, Colorado, United States

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

First Posted Date
2012-06-20
Last Posted Date
2013-11-19
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Target Recruit Count
260
Registration Number
NCT01623713
Locations
🇨🇳

Sixth Hospital of Peking University, Peking, Beijing, China

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: Iloperidone
First Posted Date
2012-02-08
Last Posted Date
2013-03-14
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
90
Registration Number
NCT01529294
Locations
🇺🇸

Novartis Investigative Site, South Miami, Florida, United States

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

First Posted Date
2011-12-23
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
42
Registration Number
NCT01498770

Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Iloperidone
First Posted Date
2011-11-03
Last Posted Date
2017-04-11
Lead Sponsor
Maurizio Fava, MD
Target Recruit Count
20
Registration Number
NCT01464229
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Relapse Prevention Study in Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
Drug: Iloperidone
First Posted Date
2011-02-08
Last Posted Date
2023-07-17
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
635
Registration Number
NCT01291511
Locations
🇺🇦

Vanda Investigive Site, Kharkiv, Ukraine

🇺🇦

Vanda Investigative Site, Vinnytsya, Ukraine

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: iloperidone
First Posted Date
2010-09-22
Last Posted Date
2013-03-15
Lead Sponsor
Novartis
Target Recruit Count
501
Registration Number
NCT01207414
Locations
🇺🇸

Comprehensive Neuroscience, Fresh Meadows, New York, United States

🇺🇸

Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States

🇺🇸

The Hospital of Central Connecticut, New Britain, Connecticut, United States

and more 53 locations

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

First Posted Date
2005-11-15
Last Posted Date
2024-12-13
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
593
Registration Number
NCT00254202
Locations
🇮🇳

Vanda Investigational Site, Chinawaltair, Visakha Patnam, India

🇮🇳

Vanda Investgational Site, Chennai, Tamilnadu, India

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy